Mortality of people with chronic fatigue syndrome: a retrospective cohort study in England and Wales from the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Clinical Record Interactive Search (CRIS) Register
Yes, you guessed it right - they are the GLP -1 (Glucagon -Like Peptide -1 agonist) drugs
Patients with thyroid disorders or a family history of medullary thyroid carcinoma (MTC) or MEN 2 should avoid GLP-1
These agents regulate glucose metabolism by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, promoting weight loss, and improving cardiovascular health (Meh et al., 2023
Do not aim the needle directly at the lyophilized powder cake at the bottom
A transparent explanation of evidence limitations and surgical risk priorities is more likely to preserve trust and compliance than confrontational dismissal